A dose‐effect study of the in vivo inhibitory effect of quinidine on sparteine oxidation in man.
Open Access
- 1 March 1990
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 29 (3) , 299-304
- https://doi.org/10.1111/j.1365-2125.1990.tb03639.x
Abstract
1. Twelve healthy extensive metabolisers of sparteine were sparteine tested daily for 6 days (19.00 h to 07.00 h). A small but statistically significant rise in sparteine metabolic ratio (MR) was observed. 2. Following 100 mg quinidine sulphate given to four of the subjects at 16.00 h, sparteine tests were carried out 19.00 h to 07.00 h on the same day and then daily for 6 days. Quinidine caused an immediate twenty‐fold increase in sparteine‐MR which then gradually returned to normal over the following 4‐6 days. Quinidine concentrations in plasma were measurable only up to 20 h after the quinidine test dose. 3. At weekly intervals, all 12 subjects received single doses of quinidine sulphate of 5, 10, 20, 40 and 80 mg at 16.00 h, each time followed by a sparteine test 19.00 h to 07.00 h on the same day. A clear dose‐effect relationship was found with a significant rise in the sparteine‐MR even after 5 mg quinidine. After 80 mg quinidine, 8 of 12 subjects became phenotypically poor metabolisers (MR greater than 20).This publication has 31 references indexed in Scilit:
- Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in manBiochemistry, 1988
- Characterization of the common genetic defect in humans deficient in debrisoquine metabolismNature, 1988
- Sparteine Oxidation Polymorphism in DenmarkActa Pharmacologica et Toxicologica, 1985
- A human cytochrome P-450 characterized by inhibition studies as the sparteine–debrisoquine monooxygenaseCanadian Journal of Physiology and Pharmacology, 1984
- Competitive inhibition of sparteine oxidation in human liver by β-adrenoceptor antagonists and other cardiovascular drugsLife Sciences, 1984
- The genetic control of sparteine and debrisoquine metabolism in man with new methods of analysing bimodal distributions.Journal of Medical Genetics, 1983
- Inhibition of sparteine oxidation in human liver by tricyclic antidepressants and other drugsLife Sciences, 1983
- A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.Journal of Medical Genetics, 1980
- Clinical Pharmacokinetics of QuinidineClinical Pharmacokinetics, 1980
- POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MANThe Lancet, 1977